{"doi":"10.1007/s40265-022-01731-1","title":"Tixagevimab + Cilgavimab: First Approval","abstract":null,"journal":"Drugs","year":2022,"id":612650,"datarank":0.6284482113039639,"base_score":4.189654742026425,"endowment":4.189654742026425,"self_citation_contribution":0.6284482113039639,"citation_network_contribution":0.0,"self_endowment_contribution":0.6284482113039639,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":65,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":6,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1559664,"name":"Susan J. Keam","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Tixagevimab + Cilgavimab: First Approval","abstract":"Tixagevimab 150 mg and cilgavimab 150 mg (EVUSHELD<sup>TM</sup> 150 mg + 150 mg solution for injection; tixagevimab + cilgavimab) is an intramuscular (IM) long-acting monoclonal antibody combination developed by AstraZeneca for the prevention and treatment of COVID-19. In March 2022, tixagevimab + cilgavimab was approved in the UK for pre-exposure prophylaxis of COVID-19 in adults who are not currently infected with SARS-CoV-2 and who have not had a known recent exposure to an individual infected with SARS-CoV-2 and who are unlikely to mount an adequate immune response to COVID-19 vaccination or for whom COVID-19 vaccination is not recommended, and in the EU for the prevention of COVID-19 in adults and adolescents aged ≥ 12 years and weighing ≥40 kg. In December 2021, tixagevimab + cilgavimab was granted Emergency Use Authorization by the US FDA for the pre-exposure prophylaxis of COVID-19 in adults and paediatric individuals (≥ 12 years of age and weighing ≥ 40 kg). This article summarizes the milestones in the development of tixagevimab + cilgavimab leading to this first approval for pre-exposure prophylaxis of COVID-19 in individuals who are not currently infected with SARS-CoV-2.","is_dataset_classified":null,"base_score":4.189654742026425,"endowment":4.189654742026425,"datacite_reuse_total":6,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"35727563","pmcid":"PMC9211051","openalex_id":"https://openalex.org/W4283258959","authors":[],"funders":[],"total_grants":0,"fwci":5.9891,"citation_percentile":0.97519667,"influential_citations":0,"citation_trend":[{"year":2022,"count":6},{"year":2023,"count":25},{"year":2024,"count":21},{"year":2025,"count":10},{"year":2026,"count":3}],"oa_status":"bronze","license":"cc-by-nc","oa_locations":[{"url":"https://link.springer.com/content/pdf/10.1007/s40265-022-01731-1.pdf","host_type":"journal"},{"url":"https://link.springer.com/content/pdf/10.1007/s40265-022-01731-1.pdf","host_type":"publisher"},{"url":"https://link.springer.com/article/10.1007/s40265-022-01731-1/fulltext.html","host_type":"publisher"},{"url":"https://doi.org/10.1007/s40265-022-01731-1","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/35727563","host_type":"repository"},{"url":"https://figshare.com/articles/online_resource/Tixagevimab_Cilgavimab_First_Approval/19783399","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/9211051","host_type":"repository"},{"url":"https://doi.org/10.6084/m9.figshare.19783399.v1","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC9211051","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC9211051?pdf=render","host_type":"Europe_PMC"}],"fields_of_study":["SARS-CoV-2 and COVID-19 Research","Immunodeficiency and Autoimmune Disorders","COVID-19 Clinical Research Studies"],"mesh_terms":["SARS-CoV-2","COVID-19 Vaccines","COVID-19 Drug Treatment","Adolescent","Adult","Antibodies, Monoclonal","Child","Humans"],"keywords":["Medicine","Coronavirus disease 2019 (COVID-19)","Vaccination","Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)","2019-20 coronavirus outbreak","Post-exposure prophylaxis","Authorization","Drug approval","Pediatrics","Intensive care medicine","Emergency medicine","Immunology","Internal medicine","Drug","Virology","Pharmacology","Outbreak","Infectious disease (medical specialty)","Disease","Human immunodeficiency virus (HIV)"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[{"doi":"10.6084/m9.figshare.19783399.v1","title":"Tixagevimab + Cilgavimab: First Approval","publisher":"Adis Journals","resource_type":"Other"},{"doi":"10.6084/m9.figshare.19783399","title":"Tixagevimab + Cilgavimab: First Approval","publisher":"Adis Journals","resource_type":"Other"},{"doi":"10.6084/m9.figshare.26663041.v1","title":"Additional file 1 of The efficacy of tixagevimab/cilgavimab (Evusheld) in prophylaxis and treatment of COVID-19 in immunocompromised patients: a systematic review and meta-analysis","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.26663041","title":"Additional file 1 of The efficacy of tixagevimab/cilgavimab (Evusheld) in prophylaxis and treatment of COVID-19 in immunocompromised patients: a systematic review and meta-analysis","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.26663044.v1","title":"Additional file 2 of The efficacy of tixagevimab/cilgavimab (Evusheld) in prophylaxis and treatment of COVID-19 in immunocompromised patients: a systematic review and meta-analysis","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.26663044","title":"Additional file 2 of The efficacy of tixagevimab/cilgavimab (Evusheld) in prophylaxis and treatment of COVID-19 in immunocompromised patients: a systematic review and meta-analysis","publisher":"figshare","resource_type":"JournalArticle"}],"clinical_trials":[],"software_tools":[],"database_accessions":[{"name":"eudract"},{"name":"nct"}],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-02T04:24:38.737599Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}